Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,200 employees and a portfolio of more than 20 commercial products. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).
Shane Cooke oversees corporate finance, commercial, human resources, business development, corporate planning and manufacturing operations, including the contract pharmaceutical services business. Mr. Cooke joined Alkermes as President upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Previously, Mr. Cooke was Head of EDT and Executive Vice President of Elan from 2007 through the merger in 2011 and concurrently served as Chief Financial Officer of Elan Corporation from 2001 to May 2011. Mr. Cooke was appointed Director of Elan in May 2005. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company of which he was a founder. Mr. Cooke also previously held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke is a chartered accountant and a graduate of University College Dublin, Ireland. Mr. Cooke currently serves on the Board of Directors of Endo International plc, Prothena Corporation plc, Neotope Biosciences and Onclave Therapeutics Limited.
Kathy Biberstein serves as Alkermes’ in-house Chief Legal Officer and Chief Compliance Officer, as well as Secretary of Alkermes plc. Ms. Biberstein held several senior legal positions prior to joining Alkermes in 2003, including General Counsel and member of the Executive Committee at Serono in Geneva, Switzerland from 1993 to 2000, where she built a worldwide legal department. Just prior to joining Alkermes, Ms. Biberstein was Of Counsel at Crowell & Moring LLC, and earlier in her career, Ms. Biberstein was a member of the Executive Board of the World Economic Forum. Ms. Biberstein received a Bachelor of Science degree from Kettering University and a Juris Doctor from the University of Michigan Law School.
Madeline Coffin leads Alkermes’ human resources team, with responsibility for global compensation and benefits, talent acquisition, employee engagement and growth and organization development. Ms. Coffin has held a number of senior human resource positions at companies including Analog Devices, Sun Microsystems, Wang Software and Bay Networks. Prior to joining Alkermes, she founded her own company, which focused on the strategic human resource needs of growing companies for clients in a broad range of industries. Ms. Coffin holds a Bachelor of Arts degree from Penn State University and a Master of Industrial and Labor Relations from Cornell University.
Elliot Ehrich leads the discovery, delivery science, research and development, project management and medical affairs functions at Alkermes. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., overseeing the successful clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. He also serves on the Scientific Advisory Boards of Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies. Dr. Ehrich was a Phi Beta Kappa graduate of Princeton University where he received a Bachelor of Arts degree in biochemistry. He worked as a research associate at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and later earned his medical degree from Columbia University, College of Physicians and Surgeons. At Stanford University, Dr. Ehrich completed a residency in internal medicine and a clinical fellowship in the Department of Immunology and Rheumatology. He was subsequently a postdoctoral research fellow at the Howard Hughes Medical Institute at Stanford University School of Medicine, in the Department of Microbiology and Immunology.
Jim Frates serves as Chief Financial Officer of Alkermes. Prior to joining Alkermes in 1998, Mr. Frates was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Mr. Frates served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. Mr. Frates serves on the Board of Directors of SAGE Therapeutics and as a Trustee and Treasurer of St. Paul’s School. Mr. Frates received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.
Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs organization, Dr. Harris oversaw global development, registration and post-registration activities for multiple small-molecule and biologic medicines for obesity, bone, oncology, diabetes and women’s health indications. Dr. Harris received a Bachelor of Science degree from Boston College and a Ph.D. in biochemistry from the University of Wisconsin. She was subsequently a postdoctoral research fellow at the Massachusetts Institute of Technology, in the Department of Chemistry.
Blair Jackson leads business development at Alkermes, encompassing licensing efforts, new product evaluation and alliance management. Since joining Alkermes in 1999, Mr. Jackson has served in various roles within the company in both a scientific and corporate capacity. Mr. Jackson received a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.
Mike Landine oversees Alkermes’ corporate development activities. Prior to leading corporate development, Mr. Landine served as Chief Financial Officer and Treasurer of Alkermes from March 1988 until June 1998. Mr. Landine is a member of the Board of Directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products. He also previously served on the Board of Directors of GTC Biotherapeutics, a biotechnology company, from 2005 to 2010. Mr. Landine received a Bachelor of Science degree in accounting from Bentley University and is a Certified Public Accountant.
Mark Namchuk leads research, pharmaceutical development and nonclinical development of the company’s early-stage product pipeline at Alkermes. Prior to joining Alkermes in 2015, Dr. Namchuk served as Senior Vice President and Interim Global Head of Research for Vertex Pharmaceuticals, leading a group of more than 450 researchers in the discovery of transformational medicines in the areas of infectious disease, oncology, inflammatory diseases, neurology and cystic fibrosis. In addition, Dr. Namchuk developed the high throughput enzymology paradigm in support of the Vertex Chemogenomics effort and co-chaired the committee responsible for new-target selection and prosecution for the company. Earlier in his career, he served as the head of the biochemistry group at Cubist Pharmaceuticals. Dr. Namchuk obtained his doctorate in bioorganic chemistry from the University of British Columbia and completed a post-doctoral fellowship at the University of California, San Francisco.
Peter Norman leads the U.S. Government Affairs and Policy function for the company, which includes federal and state initiatives as well as programs with professional and patient organizations. Prior to joining Alkermes in 2013, Mr. Norman was the head of the Washington, D.C. office for Eisai, Inc. In addition, he’s held senior positions for Amylin Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novo Nordisk and the Biotechnology Industry Organization (BIO). Mr. Norman worked on public policy and regulatory strategies not only for Alzheimer’s disease, obesity and diabetes pharmaceutical products, but also healthcare reform and reimbursement issues. He received a Bachelor of Arts degree from Adrian College and a Juris Doctor from the University of Toledo College of Law.
Rebecca Peterson directs corporate communications, including investor relations, public relations and internal communications at Alkermes. She has more than 15 years of investor relations and corporate communications experience in the biotechnology and healthcare industries. Since joining Alkermes in 2000, Ms. Peterson has evolved the communications programs to reflect the company’s late-stage pipeline and implemented programs for major product approvals and launches. From 1997 to 2000, Ms. Peterson held various communications positions at Millennium Pharmaceuticals, Inc., where she was involved in expanding the investor relations program for this high-profile biopharmaceutical company. Prior to her tenure at Millennium, she worked in the public affairs office at Brigham and Women’s Hospital. Ms. Peterson received a Bachelor of Arts degree in public health, journalism and communications from the University of Massachusetts at Amherst and a Master of Arts in health communications from Tufts University School of Medicine and Emerson College.
Gordon Pugh leads the operations functions at Alkermes, including manufacturing, quality, process development, supply chain management and information technology. Mr. Pugh is responsible for Alkermes’ four manufacturing and development sites, which supply clinical and commercial products globally, as well as the company’s third-party supply network. He also leads the enterprise risk management function. Mr. Pugh has been with Alkermes since 2002 as Vice President of operations and became Chief Operating Officer in 2007. During his tenure, he has been responsible for a variety of key areas, including product development leadership, regulatory affairs oversight, several site design and build projects, multiple steering and oversight committees addressing partnered products, strategic alliances, and the integration with Elan Drug Technologies. He has more than 30 years of operations, process development and manufacturing experience in the pharmaceutical field gained at Corning, Celltech, Charles River Laboratories and Repligen. Prior to joining Alkermes, Mr. Pugh spent eight years at Lonza Biologics Inc., ultimately as Vice President of manufacturing operations in the U.S. and Europe. He has served on the Board of Directors at KC Bio LLC since 2000. Mr. Pugh received his Bachelor of Science degree in microbiology from Cornell University and a Master of Business Administration from Northeastern University.
Srdjan (Serge) Stankovic is responsible for evolving and executing the clinical development programs for the company’s pipeline of drug candidates. Dr. Stankovic has over 20 years of experience in pharmaceutical research and development including extensive roles in leading multi-disciplinary development teams for both small molecules and biologics in the therapeutic areas of psychiatry, neurology, oncology, pain and inflammation, respiratory medicine, cardiovascular disease and stem cell therapy. Prior to joining Alkermes in 2013, Dr. Stankovic held executive management positions at Teva, UCB Pharma, Johnson & Johnson, Neurogen Corporation and Forest Laboratories. He is credited with several major new drug approvals. He completed his training in Psychiatry at the University of Belgrade, Yugoslavia and his Epidemiology training at the University of Alabama at Birmingham.
Mark Stejbach serves as Chief Commercial Officer at Alkermes and is responsible for all aspects of Alkermes’ commercial functions, including sales, marketing, managed care and trade channels, commercial analytics, public policy and the development of commercial strategy for the company’s proprietary pipeline. Mr. Stejbach has 25 years of experience in biotech and pharmaceutical marketing, sales, managed care, and finance. Prior to joining Alkermes, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as Chief Commercial Officer. He previously held senior positions at Merck & Co. and Biogen Idec Inc. Mr. Stejbach received his MBA from The Wharton School, University of Pennsylvania and a Bachelor of Science in mathematics from Virginia Tech.